INTERNATIONAL PATENT: ALENTIS THERAPEUTICS AG FILES APPLICATION FOR "ANTI-CLDN1 ANTIBODY-DRUG CONJUGATES COMPRISING MMAE AND METHODS OF USE THEREOF"

GENEVA, Nov. 3 -- ALENTIS THERAPEUTICS AG (Hegenheimermattweg 167AAllschwil4123 Basel) filed a patent application (PCT/EP2025/061405) for "ANTI-CLDN1 ANTIBODY-DRUG CONJUGATES COMPRISING MMAE AND METHODS OF USE THEREOF" on Apr 25, 2025. With publication no. WO/2025/224335, the details related to the patent application was published on Oct 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ELSON, Greg (c/o Alentis Therapeutics AGHegenheimermattweg 167A4123 Allschwil), TOSO, Alberto (c/o Alentis Therapeutics AGHegenheimermattweg 167A4123 Allschwil), MARCHIONE, Roberta (c/o Alentis Therapeutics...